Ozan BOZKURT, Ahmet Adil ESEN, Sedef GİDENER, Aykut KEFİ, Nergis MURAT, Ömer DEMİR

Effects of resveratrol on the alterations of cavernosal eNOS and LOX-1 expression in the hypercholesterolemic condition: a preliminary study

Background/aim: The aim of this study was to determine the effects of resveratrol on the alterations of cavernosal eNOS and LOX-1 mRNA expression in the hypercholesterolemic condition. Materials and methods: Twenty-one New Zealand white male rabbits were separated into three groups. Rabbits were fed with a normal dietary intake for the control group and a 2% cholesterol diet for the hypercholesterolemia and resveratrol groups for 6 weeks. Resveratrol 4 mg/kg daily was administered for the resveratrol group. Cavernosal LOX-1 and eNOS mRNA expressions were determined with realtime RT-PCR in all groups. The statistical analysis was performed with the Kruskal Wallis and Mann Whitney U tests. Results: We found no difference between mean LOX-1 mRNA expression levels in the three groups. Lower mean eNOS mRNA expression level was determined in the hypercholesterolemia group when compared with the control group (P = 0.011). Mean eNOS mRNA expression level in the resveratrol group was similar to that in the control group but significantly higher than that in the hypercholesterolemia group (P < 0.001). Conclusion: This preliminary study demonstrates the beneficial effects of resveratrol on cavernosal eNOS expression. The presence of cavernosal LOX-1 expression was also shown for the first time. Resveratrol may be an alternative option in hypercholesterolemic erectile dysfunction with further studies supporting its beneficial effects on the corpus cavernosum.

PDF

___

1. Schouten BW, Bosch JL, Bernsen RM, Blanker MH, Thomas S, Bohnen AM. Incidence rates of erectile dysfunction in the Dutch general population. Effects of definition, clinical relevance and duration of follow-up in the Krimpen Study. Int J Impot Res 2005; 17: 58-62.
2. Azadzoi KM, Saenz de Tejada I. Hypercholesterolemia impairs endothelium dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 1991; 146: 238-240.
3. Kim JH, Klyachkin ML, Svendsen E, Davies MG, Hagen PO, Carson CC. Experimental hypercholesterolemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle cell dysfunction. J Urol 1994; 151: 198-205.
4. Kim SC, Kim IK, Seo KK, Baek KJ, Lee MY. Involvement of superoxide radical in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbits. Urol Res 1997; 25: 341-346.
5. Musicki B, Burnett AL. eNOS function and dysfunction in the penis. Exp Biol Med 2006; 231: 154-165.
6. Kim SC. Hyperlipidemia and erectile dysfunction. Asian J Androl 2000; 2: 161-166.
7. Kim SC, Seo KK, Kim HW, Lee MY. The effects of isolated lipoproteins and triglyceride, combined oxidized low density lipoprotein (LDL) plus triglyceride, and combined oxidized LDL plus high density lipoprotein on the contractile and relaxation response of rabbit cavernous smooth muscle. Int J Androl 2000; 23 (Suppl. 2): 26-29.
8. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T et al. An endothelial receptor for oxidized low density lipoprotein. Nature 1997; 386: 73-77.
9. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002; 95: 89-100.
10. Ganz P. Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease. Am J Cardiol 2005; 96: 8-12.
11. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science 1992; 257: 401-403.
12. Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006; 6: 36-47.
13. Wallerath T, Li H, Godtel-Ambrust U, Schwarz PM, Forstermann U. A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide 2005; 12: 97-104.
14. Xia N, Förstermann U, Li H. Resveratrol and endothelial nitric oxide. Molecules 2014; 19: 16102-16121.
15. Soner BC, Murat N, Demir O, Guven H, Esen A, Gidener S. Evaluation of vascular smooth muscle and corpus cavernosum on hypercholesterolemia. Is resveratrol promising on erectile dysfunction? Int J Impot Res 2010; 22: 227-233.
16. Dalaklioglu S, Ozbey G. The potent relaxant effect of resveratrol in rat corpus cavernosum and its underlying mechanisms. Int J Impot Res 2013; 25: 188-193.
17. Yu W, Wan Z, Qiu XF, Chen Y, Dai YT. Resveratrol, an activator of SIRT1, restores erectile function in streptozotocin-induced diabetic rats. Asian J Androl 2013; 15: 646-651.
18. Zou J, Huang Y, Cao K, Yang G, Yin H, Len J, Hsieh TC, Wu JM. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci 2000; 68: 153-163.
19. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptasepolymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 1999; 270: 41-49.
20. Seo KK, Yun HY, Kim H, Kim SC. Involvement of endothelial nitric-oxide synthase in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbit. J Androl 1999; 20: 298-306.
21. Ahn TY, Gomez-Coronado D, Martinez V, Cuevas P, Goldstein I, Saenz de Tejada I. Enhanced contractility of rabbit corpus cavernosum smooth muscle by oxidized low density lipoproteins. Int J Impot Res 1999; 11: 9-14.
22. Penumathsa SV, Maulik N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 2009; 87: 275-286.
23. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Förstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002; 106: 1652- 1658.